Novel gene promoters could improve gene therapies for neurological diseases
Novel promoters based on those in the herpes viruses, enabled delivery of larger genes and increased the period they were active in the nervous system.
List view / Grid view
Novel promoters based on those in the herpes viruses, enabled delivery of larger genes and increased the period they were active in the nervous system.
Drug Target Review discusses how NETSseq, a novel profiling technology, is bringing new insights to neurodegenerative and psychiatric diseases.
Skin cells reprogrammed into nerves and transplanted into the stroke-damaged rat brains formed functional connections that restored mobility and touch sensation.
Ursolic acid was shown to halt the progression of chronic multiple sclerosis (MS) and reverse the damage already caused in a mouse model of the disease.
Scientists used optical photothermal spectroscopy (O-PTIR) to image murine neurons affected by early stage Alzheimer’s disease, providing insight into the progression of the disease.
Researchers have revealed a new substance that can bind well to serotonin transporters, offering a potential way to lessen the side effects of antidepressant therapies.
The novel technology allows researchers to create three-dimensional images of signal propagation and calcium concentration changes in the neocortex of live mice.
Pre-clinical studies demonstrate that inhibiting the ’epichaperome’ can restore neural networks to normal levels. Dr Barbara Wallner at Samus Therapeutics explains how targeting the epichaperome could work as a potential treatment for Alzheimer’s and other neurodegenerative diseases.
Drug Target Review explores five of the latest research developments in the field of spinal cord injury (SCI) repair.
A novel antibody has been shown to stimulate microglia to degrade amyloid plaques in a murine model of Alzheimer’s disease.
Scientists have identified two master controller regions that are essential for alpha-synuclein aggregation and could be targeted by future therapies.
Scientists have identified that the TEX264 protein and associated enzymes protect the genome from damage, which could lead to new anti-ageing and neurodegeneration therapies.
International researchers have analysed nearly 1,900 brain samples to create the Brain Atlas, the latest database released by the Human Protein Atlas (HPA) project.
Rodent models of stroke and hydrocephalus treated with ZT-1a had reduced brain swelling, according to scientists.
Researchers show Naphthyridine-Azaquinolone (NA) could be a possible future therapy able to slow the progression and improve the symptoms of Huntington’s disease.